S. Muthuramalingam

A Phase II Study of Etanercept (Enbrel), a Tumor Necrosis Factor α Inhibitor in Patients with Metastatic Breast Cancer

Srinivasan Madhusudan, Martin D. Foster, S. Muthuramalingam et al. · Clinical Cancer Research · 2004 · 204 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Study of Etanercept, a Tumor Necrosis Factor-Alpha Inhibitor, in Recurrent Ovarian Cancer

Srinivasan Madhusudan, S. Muthuramalingam, Jeremy Braybrooke et al. · Journal of Clinical Oncology · 2005 · 166 citations

Medicine, Oncology, Pharmacology +17

Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations

Alessio Cortellini, Biagio Ricciuti, Victor R. Vaz et al. · Journal for ImmunoTherapy of Cancer · 2022 · 37 citations · Full text

Medicine, Immunology, Oncology +16

Efficacy outcomes and prognostic factors from real-world patients with advanced non-small-cell lung cancer treated with first-line chemoimmunotherapy: The Spinnaker retrospective study

Giuseppe Luigi Banna, Ornella Cantale, S. Muthuramalingam et al. · International Immunopharmacology · 2022 · 30 citations · Full text

Medicine, Oncology, Chemotherapy +15

Immunotherapy-related adverse events in real-world patients with advanced non-small cell lung cancer on chemoimmunotherapy: a Spinnaker study sub-analysis

Shobana Anpalakhan, Prerana Huddar, Roya Behrouzi et al. · Frontiers in Oncology · 2023 · 12 citations · Full text

Medicine, Immunology, Oncology +17